Membrane Initiated Signaling by 1,25α-dihydroxyvitamin D3 in LNCaP Prostate Cancer Cells

  • Dennis Larsson
  • Malin Hagberg
  • Nahren Malek
  • Charlotte Kjellberg
  • Edina Senneberg
  • Neda Tahmasebifar
  • Viktoria Johansson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)


Prostate cancer (PC) is one of the most common cancers among men, and vitamin D and its metabolites are candidates for prevention and therapy of this disease. The vitamin D metabolites, 1, 25-dihydroxyvitamin D3 (1,25D) and 25-hydroxyvitamin D3, decreases cellular proliferation and invasiveness, and stimulates differentiation of PC cells. However, the underlying mechanisms are not fully clarified, and there is evidence that some of these effects of the vitamin D system are mediated by specific membrane-associated receptors/binding proteins in addition to its nuclear receptor, suggesting multiple regulatory pathways. The aim of the present study was to examine the role of membrane initiated pathways mediating effects of 1,25D on cell invasiveness in LNCaP cells. Treatment with 1,25D evoked a dose-dependent activation of the JNK/SAPK MAPK signaling pathways within 10 min, demonstrating membrane initiated signaling of 1,25D in LNCaP cells. Furthermore, treatment with 1,25D decreased LNCaP cell invasiveness by approximately 20% after 48h. Using an inhibitor (SP600125) for the JNK/SAPK MAPK signaling pathway in combination with 1,25D on LNCaP cells, the inhibitory action of 1,25D on invasiveness was eliminated. In conclusion, 1,25D decrease invasiveness of LNCaP cells by interaction with a putative membrane associated receptor, which activate membrane, initiated signaling via the JNK/SAPK MAPK signaling pathway.


Androgen Receptor LNCaP Cell LNCaP Prostate Cancer Cell Prostate Cancer Cell Proliferation Intestinal Calcium Transport 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Holick MF (2006) Vitamin D: its role in cancer prevention and treatment. Prog Bioph Mol Biol 92:49–59.CrossRefGoogle Scholar
  2. 2.
    Haussler MR, Whitfield GK, Haussler CA, et al. (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349.PubMedCrossRefGoogle Scholar
  3. 3.
    Norman AW, Mizwicki MT, Norman DP (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3:27–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Boyan BD, Bonewald LF, Sylvia VL, et al. (2002) Evidence for distinct membrane receptors for 1 alpha,25-(OH)2D3 and 24R,25-(OH)2D3 in osteoblasts. Steroids 67:235–246.PubMedCrossRefGoogle Scholar
  5. 5.
    Nemere I, Farach-Carson MC, Rohe B, et al. (2004) Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells. PNAS 101(19):7392–7397.PubMedCrossRefGoogle Scholar
  6. 6.
    Larsson D, Anderson D, Smith NM, et al. (2006) 24,25-dihydroxyvitamin D3 binds to catalase. J Cell Biochem 97(6):1259–1266.PubMedCrossRefGoogle Scholar
  7. 7.
    Nemere I, Yazzie-Atkinson D, Johns DO, et al. (2002) Biochemical characterization and purification of a binding protein for 24,25-dihydroxyvitamin D3 from chick intestine. J Endocrinol 172:211–219.PubMedCrossRefGoogle Scholar
  8. 8.
    Larsson D, Nemere I (2001) 24,25-Dihydroxyvitamin D3 and intestinal calcium transport: from receptors to physiological response. Recent Res Dev Endocrinol 2:183–198.Google Scholar
  9. 9.
    Chen TC, Holick MF (2003) Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 14(9):423–430.PubMedCrossRefGoogle Scholar
  10. 10.
    Trapman J, Brinkman AO (1996) The androgen receptor in prostate cancer. Path Res Pract 192:752–760.PubMedGoogle Scholar
  11. 11.
    Chen TC, Schwartz GG, Burnstein KL, et al. (2000) The in vitro evaluation of 25-hydroxy-vitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 6:901–908.PubMedGoogle Scholar
  12. 12.
    Migliaccio A, Castoria G, Di Domenico M, et al. (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19(20):5406–5417.PubMedCrossRefGoogle Scholar
  13. 13.
    Peterziel H, Mink S, Schonert A, et al. (1999) Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18:6322–6329.PubMedCrossRefGoogle Scholar
  14. 14.
    Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19:2435–2444.PubMedGoogle Scholar
  15. 15.
    Pearson G, Robinson F, Beers Gibson T, et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153–183.PubMedCrossRefGoogle Scholar
  16. 16.
    Ballare C, Uhrig M, Bechtold T, et al. (2003) Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23:1994–2008.PubMedCrossRefGoogle Scholar
  17. 17.
    Bhatia M, Kirkland JB, Meckling-Gill KA (1995) Monocytic differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D3 is independent of nuclear receptor binding. J Biol Chem 270:15962–15965.PubMedCrossRefGoogle Scholar
  18. 18.
    Song X, Bishop JE, Okamura WH, et al. (1998) Stimulation of phosphorylation of mitogen-activated protein kinase by 1alpha,25-dihydroxyvitamin D3 in promyelocytic NB4 leukemia cells: a structure-function study. Endocrinology 139:457–465.PubMedCrossRefGoogle Scholar
  19. 19.
    Schwartz Z, Ehland H, Sylvia VL, et al. (2002) 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 modulate growth plate chondrocyte physiology via protein kinase C-dependent phosphorylation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase. Endocrinology 143:2775–2786.PubMedCrossRefGoogle Scholar
  20. 20.
    Bonaccorsi L, Marchiani S, Ferruzzi P, et al. (2006) Non-genomic effects of the androgen receptor and Vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells. Steroids 71:304–309.PubMedCrossRefGoogle Scholar
  21. 21.
    Marchiano S, Bonaccorsi L, Ferruzzi P, et al. (2006) The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol 132:408.CrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Dennis Larsson
    • 1
  • Malin Hagberg
  • Nahren Malek
  • Charlotte Kjellberg
  • Edina Senneberg
  • Neda Tahmasebifar
  • Viktoria Johansson
  1. 1.School of Life Sciences - BiomedicineUniversity of SkövdeSkövdeSweden

Personalised recommendations